Enriched inhibition of cancer and stem-like cancer cells via STAT-3 modulating niclocelles

Nanoscale
Santosh K MisraDipanjan Pan

Abstract

We describe for the first time a therapeutic strategy to target stem-like cancer cells via STAT-3 modulation using a nanomedicine approach. Niclocelle, a niclosamide loaded rigid core mixed micelle, was synthesized from a self-assembled well-defined amphiphilic diblock copolymer and an FDA-approved signal transducer and activator of transcription factor 3. Followed by a rigorous physico-chemical characterization, niclocelles were evaluated biologically for cytotoxicity and apoptosis in human melanoma (C32) and breast cancer (MDA-MB231 and MCF-7) cells. Niclocelles were found to selectively reduce the CD44+ stem cell population in C32 cells via STAT-3 modulation.

References

Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Nov 1, 2003·Chemical Communications : Chem Comm·Dipanjan PanKaren L Wooley
Jan 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Toru KondoTetsuya Taga
Sep 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·C Hirschmann-JaxM K Brenner
Nov 19, 2004·Nature·Sheila K SinghPeter B Dirks
Nov 24, 2006·Nature·Lucia Ricci-VitianiRuggero De Maria
Jan 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·M E PrinceL E Ailles
Feb 7, 2007·Cancer Research·Chenwei LiDiane M Simeone
Jul 25, 2007·Annual Review of Cell and Developmental Biology·Neethan A LoboMichael F Clarke
Dec 7, 2007·Cancer Research·Fei Chen, Vince Castranova
Sep 24, 2009·Biochemistry·Minyong ChenWei Chen
May 11, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Wei ZhangXiaoling Fang
Aug 22, 2013·Biochemical Pharmacology·Byung-Hak KimMyoung-Hwan Kim
Dec 24, 2013·Molecular Cancer Therapeutics·Shuo YouXingming Deng
Mar 29, 2014·Cancers·Daijiro HaradaKatsuyuki Kiura
Apr 16, 2014·Cancer Letters·Yonghe LiDonald J Buchsbaum
Dec 9, 2010·ACS Medicinal Chemistry Letters·Xiaomei RenKe Ding
Aug 21, 2014·Molecular Pharmaceutics·Santosh K MisraDipanjan Pan
Oct 14, 2014·Advanced Drug Delivery Reviews·Sina EetezadiChristine Allen
Dec 1, 2014·Journal of Food and Drug Analysis·Esra Maltas

❮ Previous
Next ❯

Citations

Sep 24, 2016·ACS Applied Materials & Interfaces·Enrique A DazaDipanjan Pan
Aug 23, 2017·Artificial Cells, Nanomedicine, and Biotechnology·Sai Kiran S S PindiproluVeera Venkata Satyanarayana Reddy Karri
Oct 24, 2018·Drug Development and Industrial Pharmacy·Sai Kiran S S PindiproluKinnera Ratna Sree Ganapathineedi
Aug 23, 2016·Small·Fatemeh OstadhosseinDipanjan Pan
Feb 6, 2017·Scientific Reports·Enrique A DazaDipanjan Pan
Apr 18, 2017·Biomedit︠s︡inskai︠a︡ khimii︠a︡·A S ZhirnikE A Vorontsov
May 7, 2020·Current Cancer Drug Targets·Mamta KumariPiyong Sola
Jun 24, 2021·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Dipendra DahalDipanjan Pan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis